NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
90 S e p t e mb e r 2003 PharmaVOICE Pharma POOL Stanley BARSHAY Dr. Stephen CHANG Dr. John CURNUTTE Dr.Thomas KOESTLER Dr. Catherine STRADER ScheringPlough Implements Organizational Changes ScheringPlough has announced organiza tional changes within ScheringPlough Research Institute (SPRI) designed to fully integrate all drugdiscovery functions within SPRI, the pharmaceutical research and devel opment arm of ScheringPlough, a research based pharmaceutical company located in Kenilworth, N.J. John Curnutte, M.D., Ph.D., formerly president and CEO of DNAX Research, a wholly owned subsidiary of ScheringPlough, now reports to Catherine Strader, Ph.D., exec utive VP of discovery research at SPRI. Dr. Curnutte has assumed responsibility for all drugdiscovery activities in the SPRI labora tories in California, including research activi ties at Canji, a wholly owned subsidiary of ScheringPlough. Reporting to Dr. Curnutte in his new role is Stephen Chang, Ph.D., VP and chief scien tific officer of Canji. Dr. Chang continues to be responsible for directing the research activities of the Canji organization. Dr. Strader is responsible for directing the activities of the SPRI discovery research orga nization, which includes biological research, chemical research, and technology acquisition and external collaboration. Dr. Strader holds a Ph.D. in chemistry from the California Institute of Technology and a B.S. in chemistry from the University of Virginia. In addition, Thomas P. Koestler, Ph.D., has been appointed executive VP of world wide regulatory affairs, worldwide research quality assurance and project management, at SPRI. In this role, Dr. Koestler, 52, is focusing his efforts on globalizing regulatory affairs, sup porting critical quality assurance activities within SPRI, and strengthening the link between the global pharmaceutical business operations and SPRI through the project man agement process. He also has assumed leadership of the aller gy/inflammation therapy team, charged with developing strategies and direction for this key therapy area. Before joining ScheringPlough, Dr. Koestler served as senior VP and head of glob al regulatory affairs at Pharmacia. Dr. Koestler received his Ph.D. from the State University of New York (SUNY) at Buf falo, Roswell Park Memorial Institute, where he studied medicine and pathology. In other company news, Stanley Barshay has been appointed chairman of Schering Plough’s consumer healthcare business. Mr. Barshay’s appointment is another ele ment in the action steps implemented by Fred Hassan, ScheringPlough’s chairman and CEO, to build a strong company for the long term. Mr. Barshay has an extensive background in healthcare and related consumer products with American Home Products (now Wyeth), and led successful marketing strategies for Centrum, Robitussin, and Dimetapp. While at American Home Products he was promoted in 1987 to senior VP charged with overseeing the consumer businesses. He also served on the corporation’s finance and operations committees. He retired from Wyeth in 1997 and has remained active in the healthcare arena. Dr. Lars E. BIRGERSON Roche NamesVP,Medical Affairs Roche, Nutley, N.J., has appointed Lars E. Birgerson, M.D., Ph.D., as VP of medical affairs. In his new position, Dr. Birgerson, who is a member of the company’s senior executive manage ment group, the North American Oper ating Committee, is responsible for oversee ing medical affairs activities in the United States. Dr. Birgerson has joined Roche from Phar macia, where he was group VP of global med ical affairs, with responsibility for all medical marketing activities in the United States and overall global strategic responsibility. A licensed physician and specialist in obstetrics and gynecology, Dr. Birgerson received his medical degree from Sweden’s Uppsala University, followed by a Ph.D. in obstetrics and gynecology. He was a practicing physician before join ing Kabi Pharma in Sweden as associate med ical director for urology/gynecology and later, medical director in the same area. Within the Pharmacia & Upjohn and Pharmacia organizations, he served in several capacities, including VP of women’s health care pharma business; VP of urology and women’s healthcare business; and VP, head of corporate licensing. Dr. Birgerson has published numerous journal articles and also was a lecturer at Upp sala University. Yasuchika HASEGAWA Kunio TAKEDA Takeda Appoints Chairman and President Takeda Chemical Industries, a research based global company focused on pharmaceu ticals, has announced executive changes. Dr. Masahiko Fujino has retired from his position as chairman of the board of the Osaka, Japan based company. Kunio Takeda, previously president of the company, has assumed the position of the chairman. Yasuchika Hasegawa, a member of the board and general manager of the corpo rate planning department, has assumed the position of president. TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY 91 PharmaVOICE S e p t e m b e r 20 03 TALENT pool Mr. Takeda presides at the board of direc tors meeting and is responsible for strategic decisions on overall management issues of the Takeda Group. Mr. Hasegawa, who also is chief operating officer, is responsible for all the operational issues. Biotech POOL Dr. Kenneth W. BAIR Carl PELZEL Chiron Announces Expanded BioPharma Leadership Chiron has appointed Kenneth W. Bair, Ph.D., as senior VP, head of bio pharma research of Chi ron BioPharmaceuticals, and Carl Pelzel as senior VP of biopharma com mercial operations of Chi ron BioPharmaceuticals. Ch i ro n , Em e ry v i l l e , Calif., is a global biotech nology company. Dr. Bair has assumed responsibility for Chiron B i oPha rmaceu t i ca l s ‘ research programs, including chem i s t r y, b i o l o g y , applied biochemistry, and discovery pro jects. He also works with the research heads of Chiron’s Vaccines and Blood Testing business units to promote orga nizational synergies. Dr. Bair joins Chiron from Pharma cia, where he was VP of discovery oncol ogy. He also led oncology research pro grams during five years with Novartis Pharmaceuticals and five years with San doz Pharmaceuticals. Dr. Bair was a Damon RunyonWal ter Winchell Cancer Foundation Post doctoral Fellow at the Massachusetts Institute of Technology. He holds a Ph.D. in organic chem istry from Brandeis University and mas ter’s and bachelor’s degrees from Wayne State University. In his newly created position, Mr. Pelzel has global responsibility for sales and marketing for new and existing bio pharmaceuticals products, as well as medical affairs. Mr. Pelzel most recently was presi dent and CEO of Invenux, a drugdis covery company. He holds a bachelor’s degree in biology from Hartwick College. Dr. Andrew C. CHAN David LOGAN Genentech Announces Senior Appointments in Research and Commercial Operations The biotechnology company Genentech has added two senior executives to its research and commercial operations organizations. Andrew C. Chan, M.D., Ph.D., has been pro moted to VP of researchimmunology and David Logan has been promoted to VP of spe cialty therapeutics. Dr. Chan, 43, joined Genentech, South San Francisco, Calif., in 2001 as senior director of immunology in the research department. While at Genentech, Dr. Chan has been responsible for overseeing research programs focused on the role of the immune system in cancer and various immunological disorders. In his new position, Dr. Chan continues to supervise Genentech’s immunology research program for the treatment of immunemedi ated and inflammatory disorders. He received his bachelor’s and master’s degrees in chemistry from Northwestern Uni versity, and his medical degree and doctorate in cellular and developmental biology from the Washington University School of Medicine in St. Louis. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University School of Medicine before becoming a post doctoral clinical and research fellow at the University of California, San Francisco. Mr. Logan, 48, joined Genentech in 1987 as a clinical marketing specialist in the com pany’s field salesforce. Most recently, in 2001, Mr. Logan was named senior director of sales and marketing in the specialty therapeutics division. In his new position, Mr. Logan continues to oversee all sales and marketing activities associated with Genentech’s Growth Hormone franchise, Pulmozyme and the potential psoriasis treat ment, Raptiva. Mr. Logan holds a bachelor’s degree in communications from the University of Alabama. Duke COLLIER Mark ENYEDY Dr. Georges GEMAYEL Ann MERRIFIELD Jan VAN HEEK Genzyme Announces Expansion of Senior Management Team Genzyme has added to its senior manage ment team as the company continues to ED BELKIN The Pharmaceutical Research and Manufacturers of America has named Ed Belkin VP of communi cations. PhRMA, Washington, D.C., represents the country’s leading researchbased pharmaceutical and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. “PhRMA will be playing an increasingly active agendasetting role in health policy debates,” says PhRMA President Alan Holmer. “Ed’s track record of taking the initiative to define healthcare issues is a perfect fit with this effort. As a result, policy mak ers, the media, and the public will gain broader understanding of the cuttingedge role new, high technology medicines play in improving healthcare and delivering value to patients.” Mr. Belkin previously was a senior VP in Hill & Knowlton’s Washington office. He has worked at all levels of news gathering, decisionmaking, and management in the media and specializes in media strategy. Among his recent assignments, he provid ed counsel on the SARS epidemic to the Minister of Health for the Province of Ontario, Canada. Previously, Mr. Belkin served as senior director of communications for former U.S. Senator Dave Duren berger (RMN), advising on communications strate gies, including healthcare reform. Before that, he was man aging editor at the NBC Radio Network in Wash ington and New York. Mr. Belkin also was executive editor and news director at KYW Newsradio in Philadel phia, where he managed the country’s toprated allnews operation. Mr. Belkin is a graduate of Syracuse Univer sity with a dual bachelor of arts degree in broad cast journalism and political science. PhRMAAPPOINTS COMMUNICATIONSVP Ed Belkin has been named VP, communications, at PhRMA. 92 S e p t e mb e r 2003 PharmaVOICE TALENT pool expand. Georges Gemayel, Ph.D., has joined the company as an executive VP, with the company’s two largest business units, thera peutics and renal, reporting to him. Genzyme, Cambridge, Mass, is a global biotechnology company. Dr. Gemayel, 43, joins Genzyme after 16 years at Roche, where most recently he led one of its largest and fastestgrowing businesses, the U.S. Specialty Care unit, which includes products in oncology, transplantation, hepati tis, HIV, and dermatology. In addition to Dr. Gemayel’s appointment, Genzyme has announced several other senior management changes. Genzyme has consolidated global responsi bility for manufacturing of all therapeutic and biosurgery products under the direction of Executive VP Jan van Heek, who also oversees Genzyme Biosurgery and Genzyme Genetics. Ann Merrifield has been appointed presi dent of Genzyme Biosurgery, and continues to direct the orthopedics and biosurgical special ties businesses, including marketed products Synvisc, Sepra antiadhesion products, and Carticel. Executive VP Duke Collier directs Gen zyme’s molecular oncology and cardiovascular business units, both of which have earlystage products in clinical trials. Mr. Collier’s focus is to create significant business opportunities for Genzyme in each of these high potential areas. Mark Enyedy has been named senior VP and general manager of Genzyme Molecular Oncology, replacing Gail Maderis, who has left the company to head an early stage Cali forniabased biotechnology company. Dr.Willard DERE Amgen NamesVP,Global Inflammation Clinical Development Amgen has appointed Willard Dere, M.D., to the position of VP and head of the inflam mation therapeutic area, one of the company’s three core research and development pro grams. Amgen, Thousand Oaks, Calif., is a global biotechnology company. Dr. Dere oversees global development efforts for all new inflammation product can didates and new indications for Amgen’s cur rently marketed inflammation therapies, Enbrel and Kineret. Dr. Dere joins Amgen after nearly 14 years at Eli Lilly, where most recently he served as VP of endocrine, bone, and general medicine research and development. In addition, since 1989 Dr. Dere has held an academic appointment at Indiana Universi ty School of Medicine, where he was clinical associate professor, and hospital appointments at Wishard Memorial Hospital and Richard Roudebush Veterans Administration Medical Center. Dr. Dere received his medical and under graduate degrees from the University of Cali fornia at Davis. He pursued clinical training at the Uni versity of Utah affiliated hospitals and the University of California at San Francisco affil iated hospitals. He was an assistant professor at the University of Utah School of Medicine and held hospital appointments at the Uni versity of Utah Health Sciences Center and Veterans Administration Medical Center in Salt Lake City. David J. GURY Thomas H. MCLAIN Nabi Biopharmaceuticals Names CEO Nabi Biopharmaceuti cals has elected Thomas H. McLain, president and chief operating officer, as the company’s CEO. Nabi, Boca Raton, Fla., discovers, develops, man ufactures, and markets products that power the immune system to help people with serious, unmet medical needs. The appointment fol lows David J. Gury’s deci sion to retire. Mr. Gury, chairman and CEO for the company, has retired as CEO, but continues to serve as nonexecutive chairman of the board to the end of his term in May 2004. Roger L. HAWLEY William R. RINGO InterMune Announces Executive Management Changes InterMune has named William R. Ringo to serve as executive chair man and interim CEO, following the resignation of Scott Harkonen, M.D., president and CEO. Dr. Harkonen remains a member of the board. InterMune, Brisbane, Calif., a commercial ly driven biopharmaceutical company, also has announced that the board has established a search committee and engaged an executive search firm to identify qualified candidates to fill the position of president and CEO. Dr. Harkonen founded InterMune in February 1998. He served as a member of the board and as CEO and president since the company’s inception, and as chairman from January 2000 until May 2003. Mr. Ringo has served as a member of the board since June 2002 and was elected nonex ecutive chairman in May 2003. Previously, Mr. Ringo was with Eli Lilly, where he most recently served as product group president, oncology and critical care products, from June 1999 until his retirement in February 2001. In addition to serving on the board of InterMune, Mr. Ringo is a member of the board of directors of Praecis Pharmaceuticals, Encysive Pharmaceuticals, La Jolla Pharma ceuticals, Inspire Pharmaceuticals, and a num ber of private companies. Mr. Ringo holds a MBA from the University of Dayton. In other company news, InterMune has named Roger L. Hawley executive VP of commer cial operations. Mr. Hawley is respon sible for developing and implementing compre hensive marketing and sales strategies for the company’s three mar keted products, Infergen, Actimmune, and Amphotec, and for oritavancin, the company’s intravenous investigational antibiotic. In addition, he is responsible for longrange com mercial planning for the company. Previously, he was VP of sales for the U.S. western region for the central nervous system and gastrointestinal division at GlaxoSmith Kline. Biopharmaceutical POOL Dr. Graham BURTON Dr. Michael VANDER ZWAN Celgene Announces New Additions to Senior ManagementTeam Celgene has appointed Graham Burton, M.D., Ph.D., as senior VP of regulatory affairs, pharmacovigilence, and project management, and Michael Vander Zwan, Ph.D. as VP of quality assurance and compliance. Celgene, Warren, N.J., is an integrated biopharmaceu 93 PharmaVOICE S e p t e m b e r 20 03 TALENT pool tical company engaged primarily in the dis covery, development, and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Dr. Burton has joined Celgene with more than 15 years of strong global regulatory rela tionships. His most recent position was as senior VP of global regulatory affairs and qual ity assurance at Johnson & Johnson Pharma ceutical Research & Development. In his new role at Celgene, Dr. Burton fos ters strong relationships with global regulato ry agencies and manages the Celgene drug safety pharmacovigilence worldwide depart ment. He also is a member of the company’s senior management team. Dr. Vander Zwan has more than 25 years of pharmaceutical experience and most recently was VP of compliance and quality manage ment at Pharmacia where he developed and implemented a global compliance manage ment function. Dr. Vander Zwan also is a member of the Celgene senior management team. Dr. John MCKEARN Kalypsys Appoints Chief Scientific Officer Kalypsys has appointed John McKearn, Ph.D., as chief scientific officer. Kalypsys, La Jolla, Calif., is a biopharmaceutical company that uses advanced automation technologies to first evaluate drug candidates in cellular mod els of disease and then optimize the safety and efficacy of select candidates. Dr. McKearn formerly was the senior VP of discovery research at Pharmacia. While at Pharmacia, Dr. McKearn created an integrat ed worldwide drugdiscovery team of more than 1,600 research scientists after the merger of Pharmacia & Upjohn with Monsanto and its G.D. Searle unit. Dr. McKearn has more than 40 issued patents in the area of blood cell development, cancer, and inflammation treatment and has coauthored more than 70 peerreviewed scien tific papers. He holds a bachelor’s degree in biology from Northern Illinois University and a Ph.D. in immunology from the University of Chicago. Jerry SMITH HNS/Nova BioGenetics Appoints Pharmaceutical Business Development President Healthcare Network Solutions/Nova Bio Genetics has tapped Jerry Smith as president of pharmaceutical business development. Nova BioGenetics is a biopharmaceuticals company based in Atlanta. Mr. Smith has extensive experience in the pharmaceutical industry, serving more than 34 years at Pharmacia, PharmaciaUpjohn, and its predecessors. Mr. Smith has held positions in sales, mar keting, field research, and management. He received his bachelor of science in biology and chemistry from Arkansas State University. Lewis STUART CVTherapeutics Appoints VP of Sales CV Therapeutics has named Lewis Stuart VP of sales. In this newly created position, Mr. Stuart is responsible for the strategic leader ship and overall management of the field sales organization for Ranexa and other potential CV Therapeutics products. CV Therapeutics, Palo Alto, Calif., is a bio pharmaceutical company focused on applying molecular cardiology to the discovery, devel opment, and commercialization of novel, smallmolecule drugs for the treatment of car diovascular diseases. Mr. Stuart has joined CV Therapeutics with more than 20 years of sales and market ing experience. Mr. Stuart served for six years as VP of sales at Agouron Pharmaceuticals, a Pfizer company. He also directed the sales teams for several cardiovascular products at BristolMyers Squibb. Mr. Stuart holds a bachelor of arts in mar keting communications from Virginia Poly technic and State University. Specialty POOL Dr. Karen AUDITORE HARGREAVES Jack L. BOWMAN NeoRx Names CEO and Chief Operating Officer NeoRx has appointed Jack L. Bowman as CEO and Karen AuditoreHargreaves, Ph.D., as chief operating officer. Seattlebased NeoRx is a cancer therapeutics company that devel ops products for targeted delivery of anti cancer agents, including radiopharmaceuti cals, to tumor sites. A director of NeoRx since 1994, Mr. Bow man was appointed executive chairman and chairman of the board of directors in March 2003. He continues to serve as chairman. Previously, Mr. Bowman was company group chairman of Johnson & Johnson, a posi tion he retired from in 1993. Douglass B. Given, M.D., Ph.D., who has served as president, CEO, and a director of NeoRx since July 2001, has resigned from these positions. He is rejoining Bay City Cap ital as an excutive in residence. Dr. AuditoreHargreaves joined NeoRx as VP of research and development in May 1999 and became senior VP of research and devel opment in September 2001. Dr. AuditoreHargreaves earned a Ph.D. in genetics from the University of California, Davis, and received her postdoctoral training at the Massachusetts Institute of Technology Center for Cancer Research. Elizabeth S. CLARKE Leo PAVLIV Cumberland Appoints Senior Executives Executive appoint ments have been announced at Cumber land Pharmaceuticals, a Nashville, Tennessee based company formed to acquire and market a portfolio of niche pharma ceuticals to specific physi cian specialties, such as gastroenterology, pul monology, critical care, and emergency medicine. Leo Pavliv has been named VP of operations and Elizabeth S. Clarke has been named director of business development. Mr. Pavliv brings more than 19 years of experience developing pharmaceutical and biological products to Cumberland. In his new role, Mr. Pavliv is responsible for a combina tion of manufacturing, product development, quality affairs, and regulatory activities. He most recently served as VP of pharmaceutical development at Cato Research, a fullservice contract research and development organiza tion. He received both his degree in pharmacy and his master’s of business administration from Rutgers University. Ms. Clarke is responsible for evaluating and negotiating product acquisition agree ments and coordinating the duediligence process. Previously, she served in a number of sales, marketing, and business development roles during her eight years with Eli Lilly, including senior manager of strategic plan ning. She received both a bachelor’s in mechanical engineering and a master’s of busi 94 S e p t e mb e r 2003 PharmaVOICE TALENT pool ness administration in marketing from Van derbilt University. Dr. Arthur R. KAMM Salix Pharmaceuticals Names Senior VP, Research and Development,and Chief Development Officer Arthur R. Kamm, Ph.D., has joined Salix Pharmaceuticals as senior VP of research and development and chief development officer. Salix, Raleigh, N.C., develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Dr. Kamm has served in a consulting capacity with Salix since January 2003. He has more than 20 years of experience that spans the various aspects associated with the clinical development and regulatory approval of medical products, including proprietary and overthecounter pharmaceutical prod ucts, biotechnology products, and medical devices. Before joining Salix, Dr. Kamm was presi dent, CEO, and founder of A.R. KammAssoci ates, a strategiclevel consulting and medical product development service organization. Before founding A.R. Kamm Associates, Dr. Kamm held the posts of VP of clinical develop ment and VP of Zantac development for Glaxo. Dr. Kamm received a B.S. in biology from University of South Carolina and Ph.D. in bio chemistry from Medical College, University of Arizona. Generic POOL Sylvia S. MCBRINN Andrx Names Executive VP, Branded Pharmaceuticals Andrx has named Sylvia S. McBrinn execu tive VP of Andrx Labora tories, where she leads the company’s brand pharma ceuticals sales and mar keting efforts. Andrx, Davie, Fla., develops and commercializes bioequiv alent versions of controlledrelease brand name pharmaceuticals. She has more than 25 years of experience in the pharmaceutical industry, including U.S. and global responsibilities in sales, sales man agement, and marketing management. Most recently, Ms.McBrinnwas a VPofglob al and U.S. marketing for Bextra at Pharmacia. Ms. McBrinn began her career with Upjohn in sales, progressed to sales management, and after Upjohn merged to become Pharmacia, she moved into more senior positions in sales and marketing, including VP of global and U.S. marketing in neurology, which ultimate ly led to her being responsible for the Bextra product launch. Discovery POOL Paul HAMELIN Elitra Pharmaceuticals Announces Appointment of CEO Paul Hamelin has been promoted to CEO of Elitra Pharmaceuticals and has been elected to serve as a member of the board of directors. San Diegobased Elitra Pharmaceuticals’ focus is on antimicrobial drug discovery and focuses on the identification, development, and commercial ization of novel antimicrobial compounds. Mr. Hamelin joined Elitra in May 2002 as president and chief operating officer after spending 22 years as a pharmaceutical execu tive. Harry Hixson, the former CEO, remains as the chairman of Elitra’s board of directors. Mr. Hamelin brings significant experience to Elitra in product development and com mercialization as a senior pharmaceutical exec utive with Pharmacia, Searle, Abbott Labora tories, Eli Lilly, and most recently as senior VP of global commercial operations with Millen nium Pharmaceuticals. CRO POOL Sue DEVENISHMEARES Carolyn MAKI Brian MOONEY Susanne OLTZ Sebastian PACIOS PRA International Promotes Key Managers PRA International, a global clinical research organization based in McLean, Va., has announced several senior management promotions to support the company’s plans for con tinued expansion and growth. Brian Mooney has been promoted to VP of global project manage ment. Mr. Mooney is advancing the roll out of the PRA Compass Man agement procedures and continues to assure global project management con sistency. He operates from PRA’s office in Eaton town, N.J. Sebastian Pacios has been promoted to VP of operations , countries group. As the new head of the countries group, Mr. Pacios brings valuable experience and an interna tional perspective to this team. The countries group now includes Euro pean clinical monitoring operations, and Mr. Pacios also is managing PRA’s international partners relations. He has relocated from the Spain office to McLean, Va. Sue DevenishMeares has moved to VP of oper at i ons , Ph i l ade l ph i a office. Ms. DevenishMeares brings a sound global perspective to the Philadelphia office with her clinical research organization indus try expertise and international knowledge. She has relocated from PRA’s office in Australia. Carolyn Maki has been promoted to VP of proposals and contracts. Ms. Maki is responsible for centralizing and managing all proposals and contracts globally. Ms. Maki continues to oper ate from PRA’s office in Charlottesville, Va. Susanne Oltz has moved to VP of business operations. Ms. Oltz oversees PRA’s business operations worldwide and is based in Eaton town, N.J. Service POOL Gerard CIGNARELLA CHSWelcomes New Member to Marketing Professionals Team CHS, a provider of pharmaceutical and biotech contract marketing services, has added Gerard Cignarella to its team. Mr. Cignarella is 95 PharmaVOICE S e p t e m b e r 20 03 TALENT pool responsible for providing a broad range of mar keting solutions and bestpractices insights to his clients. Based in Scottsdale, Ariz., CHS is a subsidiary of inChord Communications, a glob al group of communications companies. Mr.Cignarella joins CHS from Nastech Phar maceutical Co., where he was senior director of global marketing and business development. He was responsible for design, implementation, and management of drugdevelopment programs. In addition, he also was responsible for all post launch commercialization activities. Mr. Cignarella is working toward his mas ter’s in business administration for market ing/finance and holds a master’s degree in phar maceutical science, both from Long Island University. He also holds a bachelor’s degree in pharmacy from St. John’s University. Susan MONTANILE MediPromotions Hires VP, Business Development Med i Promot i ons , Hasbrouck Heights, N.J., has hired Susan Montanile as VP of business develop ment. MediPromotions is a pharmaceutical market ing services provider. Ms. Montanile is responsible for developing solutionsbased personalized promotion for advertising agencies and their clients. Formerly publisher of Sports 03, Ms. Mon tanile has an extensive sales background in healthcare print and alternative media, sam pling, and compliance programs and began her career as a registered nurse. She is a gradu ate of Pennsylvania State University. Greg TURNER InfoPro Names Industry Veteran to Head Up Sales and Business Development Greg Turner has been appointed as senior director of sales and business development for North America at InfoPro Solutions, Westlake Village, Calif., which develops, implements, and maintains enterpriseclass systems for the drugdevelopment markets within the pharma ceutical and biotechnology industries. Mr. Turner has assumed responsibility for the development of new accounts and key account management for North America. Mr. Turner has more than 30 years of experience in executive sales management and the selling of highend IT solutions to Fortune 100 compa nies. He also is responsible for selling the Clin icopia Suite, which includes forecasting, pro cess execution, supply chain, labeling, and drug accountability. Before joining InfoPro Solutions, Mr. Turner held senior sales management positions at com panies such as Business Engine Software, TopTi er Software (SAP Portals), QAD, and DEC. Mr. Turner has a B.E. honors in mechanical engineering from the University of Technolo gy of Sydney, with a minor in biomedical engineering. He also studied advanced accounting and economics at Macquarie Uni versity in Sydney, Australia. Barry ZIMMERMAN Market Measures/Cozint Appoints CEO Barry Zimmerman has been appoined CEO at Market Measures/Cozint, East Hanover, N.J., a NOPWorld Health com pany, which is a unit of NOP World, a wholly owned subsidiary of U.K.based United Busi ness Media. Mr. Zimmerman joined NOP World Health in August 2002, as its executive VP of strategic account development. In that role, he helped bring pharmaceutical management endtoend research and consulting solutions, drawing on the portfolios of Market Mea sures/Cozint and its two healthcare sisters, Strategic Marketing and NOP Healthcare. In addition, he supported the successful launch of NOP World Health’s new Scrip Driver service, the first sales and marketing productivity tool that links brand health, patient dynamics, and promotional activity to prescribing decisions. Medical Education POOL Cynthia DARIN Anthia MANDARAKAS Laura NOLAN Dr. Richard SCHIFMAN Dr. Ramana YALAMANCHILI Health Learning Systems Promotes Four and Hires One Health Learning Systems (HLS), Common Health’s founding medicaleducation unit located in Wayne, N.J., has announced four promotions and one new hire to support its recent new business wins. CommonHealth is a leading healthcarecommunications resource and a WPP Group company. Cynthia DaRin has been promoted to senior VP of operations from VP of meetings management and data services. In her new role, Ms. DaRin’s responsibilities include overseeing the operations of the program man agement, medical direction, meetings man agement, and creative services departments. Ramana Yalamanchili, Ph.D., has advanced to senior VP, director of medical affairs, from VP, director of medical affairs. Dr. Yalamanchili’s respon sibilities include manag ing medical direction, medical writing, and publication planning. Laura Nolan has been promoted to VP of meet ings management and data services from senior manager of meetings. In her new role, Ms. Nolan is responsible for the overall management of those departments that produce live events, lectures, and advocacy databases. Anthia Mandarakas has been promoted to senior director of program planning and devel opment from director of program planning and development. In her new role, Ms. Man darakas is responsible for the overall manage ment of multiple program teams and plays a vital role in developing new business opportu nities. Richard Schifman, M.D., has joined Health Learning Systems as senior medical director. Before joining HLS, Dr. Schifman served as medi cal director of antiinfec tive agents at Roche Lab oratories USA. Consulting POOL Bonnie GUSTAFSSON Meaghan NELSON MBS/Vox Adds to Management Team MBS/Vox, CommonHealth’s research based consultancy unit specializing in the 96 S e p t e mb e r 2003 PharmaVOICE TALENT pool analysis of physicianpatient communication in actual inoffice visits, has added two new employees to its management team. Meaghan Nelson has joined MBS/Vox, Wayne, N.J., as an account super visor. Included in her responsibilities is the analysis and presentation of findings for much of the unit’s collection of physicianpatient com munications. Before taking the position at MBS/Vox, Ms. Nelson was employed by Morgan Stan ley as a human resource generalist. She received her master’s in sociolinguis tics from Georgetown University in 2002, where she studied under Heidi Hamilton, an MBS/Vox founding con sultant. Bonnie Gustafsson has joined MBS/Vox as an analyst. With 25 years of experience in medical publishing, Ms. Gustafsson’s primary focus at the company is on the examination of interpersonal communications within a doc tor’s office to help clients better understand the doctorpatient relationship and its poten tial impact on their brands. Before her MBS/Vox position, Ms. Gustafsson was a freelance writer, editor, and desktop publisher for a number of local and national companies. Courtney MARTIN Furia Rubel Adds Account Manager to Staff Furia Rubel Commu nications, a Perkasie, Pa. based publicrelations and consulting firm, has added Courtney Martin as its newest account manager. Ms. Martin is respon sible for coordinating the agency’s daytoday activities. Ms. Martin recently received her bache lor’s in marketing from West Chester Uni versity. During her education, she completed an internship with Express where she suc cessfully applied her studies to business. Technology POOL Juan CHARVET ISITE Expands Interactive Design and DevelopmentTeam ISITE, a Philadel phiabased Internet development and con sulting company, has strengthened its interac tive design and develop ment team by appointing Juan Charvet as interac tive developer. Mr. Charvet works as a key member of I SITE’s development team focusing on devel opment of interactive tools and multimedia applications. His responsibilities include defining the user experience and project structure, imple menting the concepts, and maintaining the project as a constantly evolving product that meets both the clients’ and their intended audiences’ needs. Before joining ISITE, Mr. Charvet served as lead programmer, designer, and Webmaster at L.F. Driscoll, and digital media specialist at MGA Partners. He graduated from The University of the Arts in Philadelphia earning a degree in mul timedia with emphasis on human/computer interaction. He also has completed two AAS degrees in computer animation and graphic design and a minor in photography. He was a fouryear recipient of the Presi dential Scholarship. Association POOL Dr. Douglas DARR Reed MCMANIGLE Patrick MORAND Pittsburgh Life Sciences Greenhouse Attracts Senior Executives The Pittsburgh Life Sciences Greenhouse (PLSG) has attracted two senior executives to Pittsburgh and added a third senior manager from the region, bolstering its management ranks. PLSG is a public/private partnership, founded by the University of Pittsburgh, Lena CHOW Barbara LEHMAN Lynn PURDY Karen YORK The Medical Marketing Association (MMA) has announced its 20032004 board of directors. The Medical Marketing Association is a San Fran ciscobased nonprofit organization comprised of marketing professionals from the pharmaceutical, device, and diagnostic industries. The board was elected by the membership and included the appointment of eight new members to its existing 25member board. Key board positions appointed include Karen York, principal consultant of The York Group, as MMA president. Ms. York is founder of the York Group, a Southern Californiabased executive and agency search firm specializing in market ing the needs of healthcare companies and the agencies that serve them. Lynn Purdy, director of marketing at Calypso Medical Technologies, has been appointed MMA presidentelect. Ms. Purdy oversees market ing activities for Calyp so, a Seattlebased early stage medicaldevice company specializing in cancer therapy. Lena Chow, chairman and chief strategic officer of Euro RSCG Life, West Coast Operations, has been named MMA VP, annual conference. Ms. Chow is president and founder of Lena Chow Euro RSCG, one of the top 50 healthcare agen cies in the United States, which became part of Euro RSCG Healthcare in 1999. In addition, Barbara Lehman, chief marketing strategist at HMI Mar keting &Advertising, has been appointed as MMA VP, INAWE Awards. Ms. Lehman is a 30year awardwinning veteran in advertising and mar keting communications. MEDICAL MARKETING ASSOCIATION ANNOUNCES NEWBOARDOFDIRECTORS TALENT pool Carnegie Mellon University, UPMC Health System, and the Commonwealth of Pennsyl vania. Douglas Darr, Ph.D., has relocated from North Carolina, where he helped build the North Carolina Biotechnology Center, to become the PLSG’s VP and chief scientific officer. In this position, Dr. Darr assists PLSG in areas involving technology development through the universities, raising funds for research, and supporting efforts to build alliances between industry and academia in the region’s lifesciences area. He received his bachelor’s degree in biolo gy, his masters in physiology, and his doctor ate in physiology, from Pennsylvania State University. Patrick Morand, who has served in several seniormanagement posi tions in lifesciences orga nizations during the past 30 years, has relocated to Pittsburgh from Chicago. Mr. Morand was recruited to serve as an executive in residence under the PLSG Executive Corps program. Mr. Morand provides direct support to local startup and emerging lifesciences companies. Mr. Morand has been an officer of three startups where he gained extensive experi ence in leading earlystage therapeutic com panies. Before joining the PLSG, he served as VP, commercial operations, for Genesis Ther apeutics Inc., a company that leveraged pro teomic/genomic research for commercializa tion. Before that, he was the executive VP at Sequitor Medical Technologies in Chicago, where he led business development. He was president and CEO of LifeSource Inc., from 1992 through 1996; and from 1970 through 1992, he was with the American Red Cross, where he served as CEO of the Baltimore and St. Paul divisions. Reed McManigle, a local veteran of technolo gy transfer in the life sci ences, has joined PLSG as the organization’s direc tor of incubator and entrepreneurial educa tion. Mr. McManigle is charged with overseeing all PLSG activities cen tered on supporting emerging lifesciences com panies and promising new technologies through the PLSG incubator and related educational pro grams. He joined the PLSG from the Universi ty of Pittsburgh, where he had been a technolo gy licensing manager for the past 10 years. Agency POOL Stephanie ALBINSON Anita CARUSO Julia FARALDO Matthew GOTIMER Chris GRUNO Larry HANNON Angela HAWK Kevin A.LEDWITH Alisa LITWIN Mickey MCDERMOTT Lisa MELONE Linda SADLER Stephen SULLIVAN Beth Tansey PELLER Renee WENTWORTH Promotions and Hires Announced at Thomas Ferguson Associates and Adient — Two CommonHealth Agencies Thomas Ferguson Associates (TFA), Com monHealth’s founding professional advertis ing and promotion unit, has announced nine advancements within its ranks as well as two new hires. CommonHealth, Parsippany, N.J., is a leading healthcarecommunications resource and a WPP Group company. CommonHealth comprises Health Learning Systems, Thomas Ferguson Associates, Adient, The Quantum Group, Noesis Healthcare Interactions, Car bon Healthcare Communications, The Xchange Group, Solara, ProCom Internation al, The Conectics Group, MBS/Vox, Enter prise IG Health, EinsonHealth, MD/Salud, Shire Health New York, CommonHealth Europe, CommonHealth Australia, and Com monHealth Kyowa. Beth Tansey Peller has been promoted to VP, associate creative director. She had been VP, group copy supervisor. Julia Faraldo has been named senior account executive. She previously was an account executive. Renee Wentworth has been promoted to copy supervisor from senior copywriter. Larry Hannon has been promoted to the position of senior copy writer from copywriter. Stephanie Albinson has advanced to senior art director from art director. Anita Caruso has been promoted to group art director. Formerly, she held the title of senior art director. Angela Hawk has been promoted to account executive from assistant account executive. Stephen Sullivan has moved to account execu tive from assistant account executive. Lisa Melone has advanced to art director from assistant art director. Mickey McDermott recently joined the agency as a senior VP, creative director. Previously, Mr. McDermott was employed by Pharmacia as global marketing man ager. Alisa Litwin also has joined the ranks of TFA as a senior copywriter. Ms. Litwin previously was employed at Jordan McGrath Case & Partners as a senior VP, creative director. In addition, Adient, a CommonHealth profes sional advertising and pro motion unit located in Wayne, N.J, has added three staff members and announced one promotion within its management ranks. Linda Sadler has been hired as executive VP and managing director. She is responsible for the overall management of a large client base of business for the agency. Before joining Adient, she worked at Sudler & Hennessey as executive VP, client ser vice director. Kevin A. Ledwith has joined the Adient staff as a senior VP, management supervisor, and is 97 PharmaVOICE S e p t e m b e r 20 03 98 S e p t e mb e r 2003 PharmaVOICE TALENT pool involved in overseeing all the promotional and advertising programs on a significant agency account. Previously, Mr. Ledwith was a group account director at The Hal Lewis Group. Chris Gruno has been hired as an imaging spe cialist for Adient, and is creating animation and interactive content for various media. Before being hired full time, Mr. Gruno had worked on a freelance basis with the group, as well as with other area agencies. Matthew Gotimer has been promoted to assis tant account executive from traffic coordinator. Erin BROWN Deb CEAPA Trent DONOHUE Tina FASCETTI Ashley FUJII Robert GIBBONS Tom LEACH Steve LEHR James NICKELL Wendi RANKIN Brenda RIZZO Jeremy ROSARIO Daniel TEPER Gerbig, Snell/Weisheimer Announces NewHires and Promotions Gerbig, Snell/Weisheimer, a fullservice marketing and advertising agency and Columbus, Ohiobased subsidiary of inChord Communications has hired Daniel Teper to serve as chief global offi cer. In this role, Mr. Teper will drive the global mar keting strategy for the agency’s business world wide. He is responsible for managing all global client relationships in the United States and Europe and for allocating GSW resources based on clients’ needs. Based in the United States, Mr. Teper also is direct ly responsible for the management and growth of GSW’s London office and interna tional operations. Mr. Teper comes to GSW with more than 18 years of experience in global pharmaceuti cal marketing, from both the agency and client side. He has led global operations for three major networks — Euro RSCG, Com monHealth, Lowe Healthcare — and has been instrumental in winning and managing numerous global pharmaceutical brand assignments, driving agency strategic contri bution, and orchestrating worldwide resources. The company also has added the following people to its staff: Deb Ceapa has been named senior creative coordinator. She is responsible for managing deadlines for her assigned accounts. Before GSW, Ms. Ceapa served as project director at Ten United. Trent Donohue has been named account supervisor. He serves as liaison between the client and creative team for one of GSW’s pharmaceutical accounts. Before GSW, Mr. Donohue served as a manager for marketing and promotions at Buchanan’s Fine Furni tureInteriors. He holds a bachelor’s degree in psychology from Capital University. Tina Fascetti has been named associate cre ative director. She oversees and helps develop creative products for clients and services with in the team. She joins GSW from Sudler & Hennessey, where she served as VP/associate creative director. She holds an associate’s degree in visual communication from the Art Institute of Pittsburgh. Robert Gibbons has been named director of broadcast production. He is responsible for supervising and coordinating all broadcast production services for the agency. Before GSW, Mr. Gibbons was selfemployed. He holds a bachelor’s degree in journalism/public relations from The Ohio State University. Tom Leach has been named senior copy writer. He acts as a handson copywriter and collaborates across the team to ensure accura cy and consistency in writing style for one of GSW’s consumer accounts. Mr. Leach most recently was chief imagination officer for Write Brain Ink. He holds a bachelor’s degree in English from the University of Maine. James Nickell has been named account director. He returns to GSW from National Century Financial Enterprises where he served as associate VP of corporate marketing and communications. He holds a bachelor’s degree in commercial design from the Center for Creative Studies. In addition, the agency has promoted staff members. Erin Brown, formerly editor, has been named copywriter. She is responsible for concepting, developing, and writing market ing, branding, and advertising materials. Ashley Fujii, formerly medical informa tion specialist, has been named senior medical liaison for GSW’s medical department. She acts as a resource in developing the quality of medical information communicated in mar keting materials. Steve Lehr, formerly account supervisor, has been named account director for GSW. Mr. Lehr is responsible for maintaining the client agency relationship and managing the strate gic development of the KeyBank account. Wendi Rankin, formerly account coordina tor, has been named account executive. She is responsible for managing the daytoday tasks for one of GSW’s pharmaceutical accounts. Brenda Rizzo, formerly medical informa tion specialist, has been named senior medical liaison for GSW’s medical department. Ms. Rizzo provides leadership in assigned pro jects, creates competitive intelligence reports and acts as a resource for all of GSW in devel oping the quality of medical information communicated in marketing materials. Jeremy Rosario, formerly art director, has been named design director. He provides overall strategic and creative direction. Kerry CAVENDER Steve KILPONEN Pace Announces Staff Additions Pace, a Lowe Health care company based in Parsippany, N.J., has announced additions of staff amid continuing business growth. Lowe Healthcare is a unit of Lowe & Partners World wide, a member of the Partnership Unit of the Interpublic Group of Companies. In client services, Kerry Cavender has joined Pace as VP, man agement supervisor. Ms. Cavender, who previously was at Pacific Communi cations, is responsible for the Pfizer U.S. Xala tan account. Steve Kilponen has joined the agency as VP, account group supervisor, from Schering Plough Healthcare to direct Pace’s consumer team. He has a wealth of both consumer and professional marketing experience spanning multiple therapeutic areas. Please send your personnel announcements to email@example.com.